After investing $18.5 billion to partner with Stone Group, AstraZeneca's earnings per share are expected to increase by double digits
Wallstreetcn·
- On February 10, AstraZeneca projected a double-digit percentage growth in adjusted earnings per share for 2026, driven by strong sales in its oncology division, offsetting the impact of core diabetes drug patent expirations.
- The company is expanding into the weight-loss drug market through a $18.5 billion partnership with China’s CSPC Pharmaceutical Group and has entered late-stage clinical trials for its oral GLP-1 drug, elecoglipron.
- Despite uncertainties stemming from U.S. drug pricing policies, AstraZeneca continues to aim for $80 billion in revenue by 2030, with critical clinical data on new drugs set to be released this year.